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There are limited data regarding the use of angiotensin convert-
ing enzyme inhibitors/angiotensin receptor blockers (ACEi/ARBs) in
acuteheart failure (AHF). Thepurpose is todetermine thepatterns of
ACEi/ARBuseat the timeofadmissionanddischarge in relation to in-
vasive hemodynamic data,mortality, andheart failure (HF) readmis-
sions. This is a retrospective single-center study in patients with AHF
who underwent right heart catheterization between January 2010
and December 2016. Patients on dialysis, evidence of shock, or in-
complete follow up were excluded. Multivariate logistic regression
analysis was used to analyze the factors associated with continua-
tion of ACEi/ARB use on discharge and its relation to mortality and
HF readmissions. The final sample was 626 patients. Patients on
ACEi/ARBonadmissionweremost likelycontinuedondischarge. The
most common reasons for stopping ACEi/ARB were worsening re-
nal function (WRF), hypotension, and hyperkalemia. Patients with
ACEi/ARBuseonadmissionhadasignificantlyhighersystemicvascu-
lar resistance (SVR) andmean arterial pressure (MAP), but lower car-
diac index (CI). PatientswithRApressuresabove themedian received
less ACEi/ARB (P =0.025) andhad significantly higher inpatientmor-
tality (P=0.048). A termultivariate logistic regression,ACEi/ARBuse
at admission was associated with less inpatient mortality; OR 0.32
95% CI (0.11 to 0.93), and this e fect extended to the subgroup of
patients with HFpEF. Patients discharged on ACEi/ARB had signifi-
cantly less 6-month HF readmissions OR 0.69 95% CI (0.48 to 0.98).
ACEi/ARB use on admission for AHF was associated with less inpa-
tientmortality including in thosewithHFpEF.
Keywords
ACE/ARB; Angiotensin converting enzyme inhibitors; Angiotensin receptor
blockers; Acute heart failure; Readmissions; Outcomes; Invasive hemodynamic
parameters
1. Introduction
The inhibition of theReninAngiotensinAldosterone Sys-
tem (RAAS) plays a key role in reducing morbidity and mor-
tality in patients with heart failure, particularly in those pa-
tients with reduced ejection fraction (HFrEF). The benefits
of the RAAS inhibition (RAASi) have been proven in land-
mark trials resulting in their incorporation as key elements of
guideline directed medical therapies (GDMT) for HFrEF [1–
3]. While there is less certainty on the benefits with RAASi
in patients with heart failure with preserved ejection fraction
(HFpEF), there may be a potential role in reducing hospital-
izations and mortality with careful patient selection [4].
There are limited high-quality data to guide use in terms
of initiation, continuation, or withdrawal of ACEi/ARB in
the setting of acute heart failure, which is typically character-
ized by escalated and maladaptive activation of the RAAS [5]
regardless of underlying ejection fraction (EF). While con-
tinuation of RAASi therapy after hospital discharge in pa-
tients with HFrEF has been associated with lower mortality
and readmission rates in prior observational studies [6], there
is still a high rate of discontinuation of ACEi/ARB therapy
during AHF due to complications such as worsening kidney
function, hypotension, hyperkalemia, and angioedema [5].
Therefore, we aimed to investigate further the patterns of
ACEi/ARB use among patients with AHF, reasons for stop-
ping these agents, hemodynamic changes associatedwith use,
and impact on clinical outcomes ofmortality andHF readmis-
sions.
2. Methods
2.1 Study design and patient selection
This study is a retrospective single center analysis of pa-
tients with clinical diagnosis of acute heart failure (AHF)-
this included patients with characteristic symptoms of short-
ness of breath/orthopnea/paroxysmal nocturnal dyspnea and
with clinical evidence of volume overload on physical exam-
ination as well as on imaging based on records review who
were admitted and underwent right heart catheterization
(RHC) at any point during the index admission at Einstein
Medical Center, Philadelphia between January 2010 to De-
cember 2016. We included patients that had complete hemo-
dynamic parameters from the concomitant RHC, and infor-
mation onmedication use including initiation of ACEi/ARBs
during admission and discharge. We excluded patients with
end stage renal disease (ESRD) and those who presentedwith
hemodynamic or clinical criteria of shock (including cardio-
genic shock) as these conditions reflect where the use of
ACEi/ARB or other guideline directed medical therapy for
heart failure therapy are limited see (Fig. S1). Patients who
died were excluded from the HF readmissions rate analysis.
The study protocol was approved by the local Institutional
Review Board.
2.2 Clinical data and outcome measures
De-identified demographic, clinical, and cardiac catheter-
ization hemodynamic data were collected by review of med-
ical records. Serum creatinine values on the day of admis-
sion and discharge were obtained; and eGFR was calculated
using the CKD-EPI equation. Heart failure with preserved
ejection fraction was defined as EF ≥ 45%. Information
on medications taken for heart failure including ACEi/ARB
use at home, on admission, and upon discharge were also
obtained. Reasons for stopping ACEi/ARBs on admission
were recorded. Clinical outcomes were identified as inpa-
tient mortality, and HF readmissions within 1 month and 6
months.
2.3 Statistical analysis
Descriptive statistics were used to analyze the demo-
graphic and outcome variables. Chi square testswere used for
categorical variables. Demographic data were compiled and
compared between patients discharged on or off ACEi/ARBs.
Differences in hemodynamic measurements were compared
using independent t-tests among patients on ACEi/ARBs
started on admission compared to those not on these med-
ications. For significantly different means, analysis of co-
variance was used to adjust for age, gender, race and ejection
fraction. Rates of HF related readmissions at 1 month and
6 months were compared between patients discharged on or
without ACEi/ARBs using Chi square. Multivariate logistic
regression analysiswas used to analyze factors associatedwith
ACEi/ARB continuation on discharge. The multivariate lo-
gistic regression between mortality or HF readmissions and
ACEi/ARB use on discharge was performed after adjusting
for age, race, gender, diabetes, hypertension, other comor-
bidities, EF ≥ 45%, eGFR on discharge, and the use of other
HF medications. SPSS by IBM version 23 was used for all
analyses.
Fig. 1. Rates of Inpatient Use of ACEi/ARB and Continuation on
Discharge among Patients with ACEi/ARB use at home (far left bar
graph). The rates of ACEi/ARB continued use on admission and on dis-
charge parallel the rates of usage at home and are on the succeeding bar
graphs respectively.
Fig. 2. Rates of Inpatient Use of ACEi/ARB and Continuation on Dis-
charge among Patients not on ACEi/ARB use at home (far left bar
graph). This graph shows lower rates of ACEi/ARB use on admission and
on discharge among those not originally on ACEi/ARB at home.
3. Results
3.1 Patient demographics
Of the final sample of 626 patients see (Fig. S1), mean age
(+/-SD) was 66.92 ± 13.63 years old. 48.1% were females;
58.1% were African Americans and 31.2% were Caucasians.
61% of subjects had an ejection fraction (EF) ≥ 45%. RHC
was done for worsening heart failure for 66% of patients, 13%
for valvular heart disease evaluation, 9% for evaluation of is-
chemia, 5% for evaluation of pulmonary hypertension and 6%
for other reasons such as intracardiac shunt evaluation, peri-
cardial tamponade, transplant evaluation and worsening re-
nal function (see Fig. S2). Demographic and baseline clinical
data in Table 1 contrast patients discharged on ACEi/ARBs
to those off ACEi/ARBs.
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Fig. 3. Reasons for Stopping ACEi/ARB on Admission with AKI and
hypotension as the leading causes.
3.2 Patterns of ACEi/ARB use
Therewere 298 (47.6%) patients thatwere onACEi/ARBs
at home prior to admission. Eighty percent of patients on
ACEi/ARBwere continued on these agents on admission and
77% were discharged on it (Fig. 1). In the other hand, 328
patients were not on ACEi/ARB at home. 42 (13%) patients
were started newly onACEi/ARB on admission and 85 (26%)
of these patients were discharged on ACEi/ARBs (Fig. 2).
Among those onACEi/ARB at home and those newly started
during the hospitalization, majority of the reasons for discon-
tinuation were worsening renal function (WRF) (60%), hy-
potension (31%), and hyperkalemia (2%) (Fig. 3).
Independent factors associated with continuation of
ACEi/ARBs on discharge were analyzed using multivariate
logistic regression analysis. Existing ACEi/ARB use at home
was highly associated with ACE/ARB on discharge OR 9.68
95%CI (6.36-14.76). Higher eGFR on dischargewas also cor-
related with ACEi/ARB use on discharge OR 1.014 95% CI
(1.008 to 1.021). Ejection fraction (EF) was inversely asso-
ciated with continuation of ACEI/ARB wherein higher EF
was associated with less odds of ACEi/ARB use on discharge
OR 0.96 95% CI (0.946 to 0.972). Racial minority (non-
African American, non-Caucasian or non-Hispanic ethnic-
ity) also predicted less ACEi/ARB on discharge OR 0.3 95%
CI (0.101- 0.897) (Table 2).
3.3 Hemodynamic parameters associated with ACEi/ARB use
The right atrial pressures (RAP) were elevated in both
groups (on ACEi/ARB vs no ACEi/ARB) withmean of 12.05
± 6.96 mmHg and mean pulmonary artery pressures were
elevated with mean of 31.82 ± 11.6 mmHg. Pulmonary
capillary wedge pressure (PCWP) was also elevated at 19.93
± 8.81 however, there were no significant differences be-
tween these pressures in those with ACEi/ARB vs those
without. The mean transpulmonary gradient was within
borderline range at 12 mmHg. Patients on ACEi/ARB on
admission were found to have significantly higher SVR and
MAP, but lower cardiac index compared to those who were
off ACEi/ARB see Table 3. We looked at patients above and
below themedian values of PCWP andRAP as thesewere the
hemodynamic parameters that coincide with signs and symp-
toms of AHF. There were no significant differences in pa-
tients with PCWPvalues above or below themedian in terms
of ACEi/ARB use P = 0.688 and inpatient death P = 0.430.
However, when we examined patients with RAP above or
below the median of 11 mmHg in our sample population, pa-
tients who had RAP above the median had significantly less
ACEi/ARB use on admission 130 vs 150 P = 0.025 and had
significantly higher rates of inpatient death 18 vs 8 P = 0.048
(see Fig. 4).
3.4 Clinical outcomes associated with ACEi/ARB use
There were 26 recorded-inpatient deaths in this cohort.
39% were from acute coronary syndromes, 23% were from
respiratory arrest related to heart failure, 19% were from
heart failurewithmultiorgan failure, 15%were from arrhyth-
mias and 4% were non-cardiac causes. After adjusting for de-
mographics and baseline comorbidities, patients who were
on ACEi/ARB at home had a significantly lower odds of in-
patient mortality OR 0.32, 95% CI (0.11 to 0.93) (see Table
S1). In a subgroup analysis looking at patients with HF with
preserved EF (HFpEF), patients on ACEi/ARB had lower
inpatient deaths compared to those without (1.3% vs 5.4%
P = 0.037). On multivariate logistic regression, ACEi/ARB
use among patients with HFpEF was still significantly associ-
ated with lower inpatient mortality OR 0.10, 95% CI (0.01 to
0.908) P = 0.041 (see Table S2).
Fig. 4. ACEi/ARB use and Inpatient Mortality Stratified by Median
RA pressure showing that among patients with higher RA pressure
above themedian, therewas a significantly lower rates of continued
ACEi/ARB use but higher rates of inpatient death.
Among those who survived and were discharged without
ACEi/ARB in the full cohort, 136 (22.7%) were readmitted
within 1 month and 255 (42.5%) were readmitted within 6
months. There was a significantly lower rate of 1-month
HF readmission among patients discharged on ACEi/ARB
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Table 1. Demographic and Clinical Characteristics of Patients.
Discharge with ACE/ARB (n = 314) OFF ACE/ARB (n = 312) P value
Mean Age (years old± SD) 65.54± 13.23 68.31± 13.92 0.01
Gender
0.472Male, n (%) 168 (53.5) 157 (50.3)
Female, n (%) 146 (46.5) 155 (49.7)
Race
< 0.0001
African American, n (%) 64.6 51.6
Caucasian, n (%) 26.4 35.9
Hispanic, n (%) 6.7 4.8
Others, n (%) 2.2 7.7
Diabetes, n (%) 149 (47.6) 155 (50) 0.575
Hypertension, n (%) 286 (91.4) 266 (85.8) 0.032
Coronary Artery disease, n (%) 143 (45.5) 143 (46.1) 0.936
Atrial fibrillation, n (%) 67 (21.3) 78 (25.2) 0.297
Smoking, n (%) 116 (37.5) 95 (31) 0.106
Ejection fraction EF≥ 45% 143 (45.5) 238 (76.3) < 0.0001
BMI 32.89± 14.32 32.41± 15.49 0.875
eGFR on admission 73.60± 29.93 58.33± 32.90 0.024
eGFR on discharge 74.72± 28.38 59.85± 36.22 0.001
Medications used (%)
ACE/ARB 229 (72.9) 69 (22.1) < 0.0001
Beta blocker use 257 (82) 228 (73) 0.01
Diuretics 232 (52.3) 212 (47.7) 0.141
Nitrates 78 (25) 66 (21.3) 0.296
Hydralazine 63 (20) 71 (23) 0.436
Digoxin 33 (10.5) 19 (6.1) 0.059
MRA 53 (17) 23 (7.4) < 0.0001
Table 2. Multivariate Logistic Regression on Predictors of
ACE/ARBs Use on Discharge.
OR 95% CI P value
Age 0.999 0.982 to 1.015 0.863
Male Referrant
Female 1.309 0.854 to 2.005 0.216
African American Referrant
Caucasian 0.677 0.424 to 1.082 0.103
Hispanic 0.697 0.290 to 1.674 0.419
Others 0.301 0.101 to 0.897 0.031
eGFR on discharge 1.014 1.008 to 1.021 < 0.0001
EF 0.958 0.946 to 0.972 < 0.0001
Diabetes 0.721 0.475 to 1.095 0.125
Hypertension 1.175 0.607 to 2.273 0.633
On ACEi/ARB at home 9.684 6.355 to 14.759 < 0.0001
(23.6% vs 36.2%) P = 0.032 while 6-month HF readmission
rates were borderline significant (38.9% vs 46.5%) P = 0.069.
In analysis of a composite of 6-month readmissions and in-
patient mortality, those with RA pressure above the median
and without ACEI/ARB had significantly higher number of
poor outcomes 55% vs 38% P < 0.001 compared to those on
an ACEI/ARB see Fig. 5.
After adjusting for age, gender, comorbidities, eGFR at
discharge and HF medication use, ACEi/ARB on discharge
was associated with lower rates of 6-month HF readmission
Fig. 5. Outcomes of inpatient death and 6 month readmissions strat-
ified by ACEi/ARB use and RA pressure above or below the median.
This figure shows more rates of inpatient death and 6 month readmissions
in the subset with both RA pressure above the median and at the same time
not on ACEi/ARB.
OR 0.69 95% CI (0.48 to 0.98) and borderline significant
for 1-month HF readmission OR 0.66 (0.44 to 1.02) (Tables
S3,4).
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Table 3. Hemodynamic Parameters Associated with ACE/ARB Use on Admission.
Hemodynamics (mean± SD) in mmHg ACE/ARB on admission (n = 346) OFF ACE/ARB (n = 280) P value
RA pressure 11.71± 6.78 12.33± 7.09 0.264
mPAP 31.7± 11.32 31.92± 11.84 0.816
PCWP 19.88± 8.58 19.98± 9.01 0.892
Transpulmonary gradient 12.18± 8.23 12.29± 9.47 0.882
PVR (dynes-sec-cm-5) 224.99± 161.53 223.49± 204.59 0.921
SVR (dynes-sec-cm-5) 1598.31± 664.68 1431.94± 629.39 0.002
SVR adjusted (Standard error) 1573 (38.06) 1459 (34.24) 0.027
MAP 96.32± 17.25 91.07± 16.77 < 0.0001
MAP adjusted (Standard error) 96.34 (0.99) 91.34 (0.90) < 0.0001
CI 2.22± 0.76 2.48± 1.06 0.001
CI adjusted (Standard error) 2.24 (0.056) 2.47 (0.050) 0.003
4. Discussion
Our study found that ACEi/ARB use was associated with
significantly lower inpatient mortality as well as lower 6
month HF readmission rates among patients admitted with
AHF. This mortality benefit also extended to the subgroup
of patients with HFpEF with acute HF exacerbation. While
the clinical benefits in the use of ACEi/ARB for patients with
chronic HFrEF are well established [2, 3], there are less high-
quality data guiding the management of RAASi in patients
admitted with acute HF. This results in marked heterogene-
ity in clinical practice with respect to continuation, escalation
or cessation of RAASi in acuteHF in patientswithHFrEF [5].
There is also less evidence supporting routine use of RAASi
in patients with chronic HFpEF, which remains difficult to
treat due to its different phenotype and unique multifacto-
rial pathophysiology [7–11]. Various studies have shown
that ACEi/ARB mainly showed benefits in reduced HF hos-
pitalizations, but no significant effect on all-cause mortality
and cardiovascular mortality [9–11]. However, in a meta-
analysis, the use of ACEI in HFpEF showed an all-cause mor-
tality benefit (RR = 0.91, 95% CI = 0.87-0.95) [4]. Several
factors may contribute to the lack of demonstrable benefits
with RAASi in HFpEF including the lack of a clear consen-
sus on the definition of HFpEF which can lead to significant
heterogeneity in clinical profiles, exercise capacity, and rel-
evant clinical end points [12]. It should also be noted that
the major trials looking at ACEi/ARB in patients with HF-
pEF were not done in the setting of AHF [9–11]. In an
analysis of the DOSE-AHF (Diuretic Optimization Strate-
gies in Acute Heart Failure) and CARRESS-HF (Cardiore-
nal Rescue Study in Acute Decompensated Heart Failure) tri-
als [13, 14] by Mentz et al., although patients with HFpEF
tended to have lower baseline aldosterone levels compared
to HFrEF, biomarkers for RAAS activation (plasma renin ac-
tivity and serum aldosterone levels) were nevertheless ele-
vated [15], suggesting that at least in AHF, there is a simi-
lar mal-adaptive activation of the RAAS. This provides plau-
sibility to the hypothesis that RAASi may be beneficial in
AHF with potential to modify the vulnerable post hospital-
ization course regardless of underlying EF. In addition to the
effects of ACEi/ARBs directly on the RAAS system, ACEi
were also shown to decrease inflammatory chemokines such
as interleukins that may be useful in targeting the inflam-
matory pathway of heart failure and cardiorenal syndrome
[16]. ACEi inhibit bradykinin breakdown which may have
actions including vasodilation, fibrinolysis, and inhibition of
cell growth that may contribute to its HF benefits but at the
same time side effects such as cough and angioedema [17].
Meanwhile, angiotensin type I receptor blockade with ARBs
can lead to more angiotensin II receptor stimulation which
also has vasodilatory and antiproliferative effects that may
be beneficial with less associated adverse effects from the
bradykinin system [17, 18]. However, whether clinical out-
comes among patients who received ACEi vs ARBs were dif-
ferent in this analysis due to plausible neurohormonal effects
and/or any component of the effects of ACEi/ARB on the
inflammatory pathway in HF needs further study.
Serial measurements by Packer et al. showed that ACEi
acutely lowered right and left ventricular filling pressures,
mean arterial pressure, heart rate, systemic and pulmonary
vascular resistance in severe HF. RAASi decreases preload
and afterload through blocking vasoconstrictive effect of an-
giotensin II [19]. However, hemodynamic parameters in
our study revealed patients in AHF (in the absence of car-
diogenic shock) and on ACEi/ARB therapy had significantly
higher mean SVR and MAP, and lower cardiac index com-
pared to those not on these medications. Although temporal
relationships between these hemodynamic parameters and
ACEi/ARB use could not be established in this study, pa-
tients in AHF usually have precipitating factors that lead to
decompensation. Especially in patients with HFpEF, higher
blood pressure reflecting a higher SVR and afterload may
trigger AHF wherein ACEi/ARB use is appropriate and po-
tentially therapeutic [20]. We also found that patients with
RAP above the median received less ACEi/ARB but had sig-
nificantly higher rates of inpatient mortality and readmis-
sions. This is consistent with previous studies that an ele-
vated central venous pressure or right atrial pressure was di-
rectly associated with renal outcomes and all-cause mortality
in patients with cardiovascular disease [21, 22]. These find-
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ings also suggest that there is really no standardized clinical
guidance on the use of ACEi/ARB in patients with AHF and
oftentimes, these medications are suspended. These patients
with high right atrial pressure likely have concomitant car-
diorenal syndrome [23] and that these findings reflect a re-
flexive tendency of clinicians to indiscriminately stop these
agents due to concerns for WRF, despite the potential for
optimizing the neurohormonal changes seen with acute HF
with the use of these drug classes.
The main reasons for ACEi/ARB discontinuation in our
study were azotemia (60%), hypotension (31%), and hyper-
kalemia (2%). Our findings are consistent withmultiple prior
studies have described same factors for withdrawal or as bar-
rier for initiation of RAASi [5, 6, 24, 25]. Perceived risk for
or real decline of renal function is one of the common trig-
gers for RAASi withdrawal in clinical practice. However,
elevation of serum creatinine and BUN to a greater extent
in AHF likely only reflect hemodynamic changes in the set-
ting of cardiorenal syndrome, and not necessarily intrinsic
renal damage [26]. Elevated right sided filling pressures (as
what was seen in our sample population), translating to ele-
vated renal venous pressures and subsequent decreased renal
blood flow, coupled with elevated levels of RAAS and neuro-
hormonal activation leading to preglomerular vasoconstric-
tion may lead to the reduced GFR characteristic of cardiore-
nal syndrome [23]. This pathophysiologic condition actually
benefits from careful ACEi/ARB administration rather ces-
sation. In the CONSENSUS trial, there was a marked reduc-
tion in HF-associated mortality and symptom burden [3] and
that trends of rise in serum creatine were mostly during early
phase and returned within 30% of baseline thereafter [27].
A meta-analysis by Flather et al. on ACEi in AHF showed
that discontinuationwas rarely necessary despite higher rates
of azotemia in the treatment versus placebo arms [28]. The
critical need to ensure optimal delivery of ACEi/ARB, espe-
cially during and after vulnerable period of AHF despite el-
evation of serum creatinine, are missed opportunities to im-
prove clinical outcomes with these patients [5].
In the setting of WRF and AHF, biomarkers of intrin-
sic kidney injury are valuable in clinical decision-making on
RAASi use [23]. Validated biomarkers of tubular injury,
urine microscopy and urinary sediment analysis are simple
and readily available tests to distinguish intrinsic AKI (typ-
ically with superimposed sepsis or shock) from functional
changes in serum creatinine [5, 23]. The use of commercially
available biomarkers of tubular injury such as serum and
urine NGAL (neutrophil gelatinase-associated lipocalin), and
the combination of TIMP-2 and IGFBP7 (tissue inhibitor of
metalloproteinase-2 and insulin-like growth factor-binding
protein 7 respectively) can detect early intrinsic tubular in-
jury and may play a role when they are negative in ensur-
ing appropriate continuation of RAASi in the setting of AHF
despite benign fluctuations in markers of glomerular injury
such as serum cystatin and serum creatinine [29, 30].
Hyperkalemia is another legitimate yet infrequent reason
for discontinuation of ACEi/ARB in this study. Collins et al.
demonstrated that the presence of HF considerably increased
fatal risks of hyperkalemia in patients onRAASi therapy [31].
In the Hyperkalaemia Randomized Intervention Multidose
SZC Maintenance (HARMONIZE) trial, a subgroup analy-
sis in patients with HF and hyperkalemia showed that use
of sodium zirconium cyclosilicate achieved normokalemia
in 93% of patients within 48-h without the need to ad-
just the RAASi doses [32]. Hence, the use of novel oral
anti-hyperkalemic agents such as sodium zirconium cyclosil-
icate or patiromer can prove as valuable tools in optimizing
ACEi/ARBs use in AHF [33, 34].
Finally, contextual prescription patterns seem to be a fac-
tor in the continuation of ACEi/ARB use in AHF. Our study
found that independent of baseline co-morbidities, prior us-
age was a factor that is strongly associated with discharge
therapy of ACEi/ARB. The same pattern of use was reported
in a large observational data using Get With the Guidelines-
Heart Failure (GWTG-HF) registry, to which 88.5% usage
of ACEi/ARB prior to hospitalization persisted from admis-
sion through discharge of AHF in thosewith reduced EF [35].
Physician reluctance to alter a patient’s existing medical reg-
imen may have contributed to these findings [35]. Contin-
ued physician and provider education about the benefits of
continuation ofACEi/ARB iswarranted to achieve improved
outcomes in AHF.
5. Strengths and limitations
Our study has all the limitations of a retrospective and
single-center analyses. Data were collected from electronic
medical records and some laboratory values such as the ac-
tual potassium levels were not provided and included as part
of the analyses. The temporal relationships between the
invasive hemodynamic parameters and use of ACEi/ARBs
cannot fully be established. Data on whether ACEi/ARBs
were stopped midway during the course of admission was
not available andmay potentially influence some clinical out-
comes. ACEi/ARBs were also analyzed together and differ-
ences in the mechanism and relation of ACEi compared to
ARB in heart failure and cardiorenal syndrome pathophysiol-
ogymay also influence outcomes. Overall patient compliance
to GDMT was not assessed. The specific doses used for each
individual ACEi/ARBs were not considered in this analy-
sis. Compliance with the other components of the guideline-
directed medical therapy for heart failure was not a part of
the scope of this study but were partly accounted for their
effect in the multivariate analyses of the outcomes. Use of
other anti-hypertensive medications such as calcium channel
blockers and centrally acting agents were not accounted for
andmay influence blood pressure and heart failure outcomes.
Our institution predominantly serves patients from the low
socio-economic stratum, compliance to GDMT and diuret-
ics is a limitation. Time to diuretic use on admission was
also not documented. Nevertheless, this study has a reason-
ably large sample size with females (48%) and African Ameri-
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cans (58%) adequately represented. These are the population
groups who are usually under-represented in cardiovascular
studies [36]. This study is also the first to our knowledge to
explore hemodynamic parameters in relation to ACEi/ARB
use and quantify evidence that use of ACEi/ARB in the set-
ting of AHF can have clinical benefits across strata of ejection
fraction.
6. Conclusions
Patients on ACEi/ARB at home are most likely to con-
tinue these medications on admission and upon discharge
after AHF. Most common causes cited for withdrawal of
RAASi while in-hospital were WRF, hypotension, and hy-
perkalemia. ACEi/ARB use on admission was associated
with significantly less inpatient mortality while ACEi/ARB
on discharge was associated with less 6-month HF readmis-
sions, including in patients with HFpEF.
Author contributions
All authors were involved with study conceptualization
and planning. KBL, HMT,GS, JJ, RB, EQ collected data, KBL
summarized and analyzed the data. KBL GS and EQ drafted
the first version. All authors contributed edits, read and ap-
proved the final manuscript version.
Ethics approval and consent to participate
The study was approved by the Institutional Review
Board at Einstein Medical Center Philadelphia IRB-2020-
431. Waiver of consentwas done for this retrospective study.
Acknowledgment
There are no acknowledgments to disclose.
Funding
This research received no external funding.
Conflict of interest
None declared, no funding, this studywas approved by our
local Institutional Review Board. All authors included in this
manuscript contributed significantly in various aspects of the
study from study conceptualization, analysis, drafting and re-
view or editing of the manuscript.
Supplementarymaterial
Supplementary material associated with this article can be
found, in the online version, at https://rcm.imrpress.com/E
N/10.31083/j.rcm.2021.01.216.
References
[1] Yancy Clyde W, Jessup M, Bozkurt B, Butler J, Casey Donald E,
Colvin Monica M, et al. 2017 ACC/AHA/HFSA focused update of
the 2013 ACCF/AHA guideline for the management of heart fail-
ure: a report of the American College of Cardiology/American
Heart Association task force on clinical practice guidelines and
the heart failure society of America. Circulation. 2017; 136: e137-
e161.
[2] Yusuf S, Pitt B, Davis CE, HoodWB, Cohn JN. Effect of enalapril
on survival in patients with reduced left ventricular ejection
fractions and congestive heart failure. New England Journal of
Medicine. 1991; 325: 293-302.
[3] Swedberg K, Kjekshus J. Effects of enalapril on mortality in severe
congestive heart failure: results of the Cooperative North Scandi-
navian Enalapril Survival Study (CONSENSUS). American Jour-
nal of Cardiology. 1988; 62: 60A-66A.
[4] Khan MS, Fonarow GC, Khan H, Greene SJ, Anker SD, Gheo-
rghiade M, et al. Renin-angiotensin blockade in heart failure with
preserved ejection fraction: a systematic review andmeta-analysis.
ESC Heart Fail. 2017; 4: 402-408.
[5] Oliveros E, Oni E, Shahzad A, Kluger A, Lo K, Rangaswami J, et al.
Benefits and risks of continuing angiotensin-converting enzyme
inhibitors, angiotensin ii receptor antagonists, and mineralocor-
ticoid receptor antagonists during hospitalizations for acute heart
failure. Cardiorenal Medicine. 2020; 10: 69-84.
[6] Gilstrap LG, Fonarow GC, Desai AS, Liang L, Matsouaka R,
DeVore AD, et al. Initiation, continuation, or withdrawal of
angiotensin‐converting enzyme inhibitors/angiotensin receptor
blockers and outcomes in patients hospitalized with heart failure
with reduced ejection fraction. Journal of the American Heart As-
sociation. 2017; 6: e004675.
[7] Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett
B, et al. Spironolactone for heart failure with preserved ejection
fraction.NewEngland Journal ofMedicine. 2014; 370: 1383-1392.
[8] Solomon SD,McMurray JJV, Anand IS, Ge J, Lam CSP,Maggioni
AP, et al. Angiotensin-neprilysin inhibition in heart failure with
preserved ejection fraction. New England Journal of Medicine.
2019; 381: 1609-1620.
[9] Yusuf S, PfefferMA, SwedbergK, Granger CB, Held P,McMurray
JJ, et al. Effects of candesartan in patients with chronic heart fail-
ure and preserved left-ventricular ejection fraction: the CHARM-
Preserved Trial. Lancet. 2003; 362: 777-781.
[10] Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R,
Zile MR, et al. Irbesartan in patients with heart failure and pre-
served ejection fraction. New England Journal of Medicine. 2008;
359: 2456-2467.
[11] Cleland JGF, Tendera M, Adamus J, Freemantle N, Polonski L,
Taylor J. The perindopril in elderly people with chronic heart fail-
ure (PEP-CHF) study. European Heart Journal. 2007; 27: 2338-
2345.
[12] Ho JE, Zern EK, Wooster L, Bailey CS, Cunningham T, Eisman
AS, et al. Differential clinical profiles, exercise responses, and out-
comes associated with existing HFpEF definitions. Circulation.
2019; 140: 353-365.
[13] Bart BA, Goldsmith SR, Lee KL, Redfield MM, Felker GM,
O’Connor CM, et al. Cardiorenal Rescue study in acute decompen-
sated heart failure: rationale and design of CARRESS-HF, for the
heart failure clinical research network. Journal of Cardiac Failure.
2012; 18: 176-182.
[14] Felker GM, LeeKL, Bull DA, RedfieldMM, Stevenson LW,Gold-
smith SR, et al. Diuretic strategies in patients with acute decom-
pensated heart failure. New England Journal of Medicine. 2011;
364: 797-805.
[15] Mentz RJ, Stevens SR, DeVore AD, Lala A, Vader JM,
AbouEzzeddine OF, et al. Decongestion strategies and renin-
angiotensin-aldosterone system activation in acute heart failure.
JACC: Heart Failure. 2015; 3: 97-107.
[16] Gullestad L, Aukrust P, Ueland T, Espevik T, Yee G, Vagelos R, et
al. Effect of high-versus low-dose angiotensin converting enzyme
inhibition on cytokine levels in chronic heart failure. Journal of
the American College of Cardiology. 1999; 34: 2061-2067.
[17] McMurray JJ, PfefferMA, Swedberg K, Dzau VJ.Which inhibitor
of the renin-angiotensin system should be used in chronic heart
failure and acute myocardial infarction? Circulation. 2004; 110:
3281-3288.
[18] Abadir PM, Carey RM, Siragy HM. Angiotensin at2 receptors di-
rectly stimulate renal nitric oxide in bradykinin B2-receptor-null
mice. Hypertension. 2003; 42: 600-604.
Volume 22, Number 1, 2021 205
[19] Packer M, Lee WH, Yushak M, Medina N. Comparison of cap-
topril and enalapril in patients with severe chronic heart failure.
New England Journal of Medicine. 1986; 315: 847-853.
[20] Cotter G,Moshkovitz Y,MilovanovO, Salah A, Blatt A, Krakover
R, et al. Acute heart failure: a novel approach to its pathogenesis
and treatment. European Journal of Heart Failure. 2002; 4: 227-
234.
[21] Damman K, van Deursen VM, Navis G, Voors AA, van Veld-
huisen DJ, Hillege HL. Increased central venous pressure is asso-
ciated with impaired renal function and mortality in a broad spec-
trum of patients with cardiovascular disease. Journal of the Amer-
ican College of Cardiology. 2009; 53: 582-588.
[22] Nohria A, Hasselblad V, Stebbins A, Pauly DF, FonarowGC, Shah
M, et al. Cardiorenal interactions. Journal of the American College
of Cardiology. 2008; 51: 1268-1274.
[23] Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine
KL, et al. Cardiorenal syndrome: classification, pathophysiology,
diagnosis, and treatment strategies: a scientific statement from the
American Heart Association. Circulation. 2019; 139: e840-e878.
[24] Ahmed A, Centor RM, Weaver MT, Perry GJ. A propensity
score analysis of the impact of angiotensin-converting enzyme in-
hibitors on long-term survival of older adults with heart failure
and perceived contraindications. American Heart Journal. 2005;
149: 737-743.
[25] Palazzuoli A, Ruocco G, Ronco C, McCullough PA. Loop diuret-
ics in acute heart failure: beyond the decongestive relief for the
kidney. Critical Care. 2015; 19: 296.
[26] Ahmad T, Jackson K, Rao VS, Tang WHW, Brisco-Bacik MA,
Chen HH, et al. Worsening renal function in patients with acute
heart failure undergoing aggressive diuresis is not associated with
tubular injury. Circulation. 2018; 137: 2016-2028.
[27] Ljungman S, Kjekshus J, Swedberg K. Renal function in severe
congestive heart failure during treatment with enalapril (the Co-
operative North Scandinavian Enalapril Survival Study [CON-
SENSUS] Trial). American Journal of Cardiology. 1992; 70: 479-
487.
[28] Flather MD, Yusuf S, Køber L, Pfeffer M, Hall A, Murray G, et al.
Long-termACE-inhibitor therapy in patients with heart failure or
left-ventricular dysfunction: a systematic overview of data from
individual patients. Lancet. 2000; 355: 1575-1581.
[29] HaaseM, BellomoR,Devarajan P, Schlattmann P, Haase-Fielitz A.
Accuracy of Neutrophil Gelatinase-Associated Lipocalin (NGAL)
in diagnosis and prognosis in acute kidney injury: a systematic
review and meta-analysis. American Journal of Kidney Diseases.
2009; 54: 1012-1024.
[30] Kashani K, Al-Khafaji A, Ardiles T, Artigas A, Bagshaw SM, Bell
M, et al. Discovery and validation of cell cycle arrest biomarkers in
human acute kidney injury. Critical Care. 2013; 17: R25.
[31] Collins AJ, Pitt B, Reaven N, Funk S, McGaughey K, Wilson D,
et al. Association of serum potassium with all-cause mortality in
patients with and without heart failure, chronic kidney disease,
and/or diabetes. American Journal of Nephrology. 2018; 46: 213-
221.
[32] Anker SD, KosiborodM, Zannad F, Piña IL, McCullough PA, Fil-
ippatos G, et al.Maintenance of serum potassiumwith sodium zir-
conium cyclosilicate (ZS-9) in heart failure patients: results from
a phase 3 randomized, double-blind, placebo-controlled trial. Eu-
ropean Journal of Heart Failure. 2015; 17: 1050-1056.
[33] Kosiborod M, Peacock WF, Packham DK. Sodium zirconium cy-
closilicate for urgent therapy of severe hyperkalemia. New Eng-
land Journal of Medicine. 2015; 372: 1577-1578.
[34] Beccari M, Meaney C. Clinical utility of patiromer, sodium zirco-
nium cyclosilicate, and sodium polystyrene sulfonate for the treat-
ment of hyperkalemia: an evidence-based review. Core Evidence.
2017; 12: 11-24.
[35] Krantz MJ, Ambardekar AV, Kaltenbach L, Hernandez AF, Hei-
denreich PA, Fonarow GC. Patterns and predictors of evidence-
based medication continuation among hospitalized heart failure
patients (from GetWith the Guidelines-Heart Failure). American
Journal of Cardiology. 2011; 107: 1818-1823.
[36] Khan Muhammad S, Shahid I, Siddiqi Tariq J, Khan Safi U, War-
raich Haider J, Greene Stephen J, et al. Ten‐year trends in rn-
rollment of women and minorities in pivotal trials supporting
recent US food and drug administration approval of novel car-
diometabolic drugs. Journal of the American Heart Association.
2020; 9: e015594.
206 Volume 22, Number 1, 2021
